Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Years of Age

Therapy Clinical Trial

— EXCIN2  

Official title:

Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Years of Age. A Multicenter Clinical Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03177863
• Other study ID #: EX CIN 2 001
• Status: Completed
• Phase: N/A
• Start date: June 12, 2017
• Est. completion date: June 24, 2021

Study information

• Verified date: October 2022
• Source: Sahlgrenska University Hospital, Sweden
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In the Swedish organised cervical screening program precursors of cervical cancer are detected and treated. Most precursor lesions detected by screening heal spontaneously. Those who progress do it slowly. There are three levels from light; CIN1, moderate; CIN2 to severe; CIN3. Women with CIN3 are always treated, regardless of age, according to current clinical guidelines. Women with CIN2 who are below the age of 25 years are offered active expectance for up to two years because there is good evidence that they will spontaneously heal their lesions (regression) in 40-70% of the cases during that time. Method of treatment is today an excisional procedure of the cervix most often by Large loop excision of the transformation zone (LLETZ/LEEP) Treatment increases the risk of premature birth in a future pregnancy. In 2015 about 1800 excisional procedures of the transformation zone of the cervix were performed in the Västra Götalands regionen (VGR) om Sweden. The average age of first-time mothers in Sweden is rising and in 2014 it was 29 years. Postponed childbearing raises the question whether it is possible to refrain from surgery even for the group of women over 25 years old, with proven CIN2. Existing studies suggest that cure of CIN2 in the age group of and above 25 takes place in the same extent as under 25 years of age.There is lack of evidence concerning clinical follow-up. In a prospective multicenter clinical cohort study (observational study) with careful monitoring, the investigators will examine what proportion of CIN2 changes regress spontaneously within two years in women, 25-30 years old, and if human papillomavirus (HPV) type 16 may can be a marker for poor regression in this group. Instead of LLETZ, active expectance is offered to women this age with CIN2 in five gynecological clinics in VGR. The study protocol includes gynecologist visits every 6 months for two years, including cytology, colposcopy and directed biopsies of the cervix. Power calculation shows 160 women needs to be included, which is expected to occur within one year from the start.

Description:

Available in Swedish

Recruitment information / eligibility

• Status: Completed
• Enrollment: 125
• Est. completion date: June 24, 2021
• Est. primary completion date: June 24, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 25 Years to 30 Years

Eligibility

Inclusion Criteria:

• CIN 2
• Written consent

Exclusion Criteria:

• CIN (any grade) not resolved
• Former treatment of CIN
• Immunomodulating medication
• Pregnancy (at start of study)

Related Conditions & MeSH terms

• Cervical Intraepithelial Neoplasia
• CIN2
• Therapy

Intervention

Procedure:
• Expectancy
Clinical monitoring. See arm description

Locations

Country	Name	City	State
Sweden	Södra Älvsborgs Sjukhus	Borås
Sweden	Frölunda specialistsjukhus	Göteborg
Sweden	Kungshöjds gynekologmottagning	Göteborg
Sweden	Skaraborgs sjukhus, kvinnokliniken	Skövde
Sweden	Norra Älvsborgs sjukhus, kvinnokliniken	Trollhättan

Sponsors (1)

Lead Sponsor	Collaborator
Sahlgrenska University Hospital, Sweden

Country where clinical trial is conducted

Sweden, 

References & Publications (8)

Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009 Jan;113(1):18-25. doi: 10.1097/AOG.0b013e31818f5008. — View Citation

Discacciati MG, de Souza CA, d'Otavianno MG, Ângelo-Andrade LA, Westin MC, Rabelo-Santos SH, Zeferino LC. Outcome of expectant management of cervical intraepithelial neoplasia grade 2 in women followed for 12 months. Eur J Obstet Gynecol Reprod Biol. 2011 — View Citation

Guedes AC, Zeferino LC, Syrjänen KJ, Brenna SM. Short-term outcome of cervical intraepithelial neoplasia grade 2: considerations for management strategies and reproducibility of diagnosis. Anticancer Res. 2010 Jun;30(6):2319-23. — View Citation

Ho GY, Einstein MH, Romney SL, Kadish AS, Abadi M, Mikhail M, Basu J, Thysen B, Reimers L, Palan PR, Trim S, Soroudi N, Burk RD; Albert Einstein Cervix Dysplasia Clinical Consortium. Risk factors for persistent cervical intraepithelial neoplasia grades 1 — View Citation

Kyrgiou M, Mitra A, Arbyn M, Stasinou SM, Martin-Hirsch P, Bennett P, Paraskevaidis E. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ. 2014 Oct 28;349:g6192. doi: 10.1136/bmj.g6192. Review. — View Citation

Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW; 2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013 Apr;121(4):829-846. doi: 10.1097/AOG.0b013e3182883a34. — View Citation

Ostör AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993 Apr;12(2):186-92. Review. — View Citation

Wilkinson TM, Sykes PH, Simcock B, Petrich S. Recurrence of high-grade cervical abnormalities following conservative management of cervical intraepithelial neoplasia grade 2. Am J Obstet Gynecol. 2015 Jun;212(6):769.e1-7. doi: 10.1016/j.ajog.2015.01.010. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of regress	Proportion of women with CIN2 at inclusion who will regress to CIN1 or no evidence of disease	24 months from date of visit when CIN2 was diagnosed
Secondary	Proportion of regress for women with HPV16	Proportion of women with CIN2 and HPV 16 at inclusion who will regress to CIN1 or no evidence of disease	Proportion of women with CIN2 at inclusion who will regress to CIN1 or no evidence of disease